Ambrx: Funding, Investors & Team (Sep 2026)
Ambrx is a biopharmaceutical company in the clinical stage that applies a genetic code technology platform to find and create Engineered Precision Biologics. These consist of next-generation medications that connect antibodies to drugs, bispecific drugs, targeted therapies in the field of immune-oncology, unique cytokines that modify the immune system, and long-lasting peptides to treat metabolic and cardiovascular disorders. Ambrx is progressing with a broad range of clinical and preclinical programs to enhance effectiveness, safety, and convenience, in many medical fields, such as its principal candidate, ARX788.
Ambrx has raised $75.0M across 1 funding round on record, the most recent an undisclosed round of $75.0M announced in May 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ambrx Company Profile and Key Stats
Latest funding round on record: May 2023.
Ambrx Funding Rounds
Ambrx Founders and Leadership Team
No contact details are on record for this team yet.
Ambrx Funding Compared to Other Biotechnology Startups
Ambrx's latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ambrx in Biotechnology and La Jolla
Companies Similar to Ambrx
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Ambrx Funding FAQs
What does Ambrx do?
Ambrx is a biopharmaceutical company in the clinical stage that applies a genetic code technology platform to find and create Engineered Precision Biologics. These consist of next-generation medications that connect antibodies to drugs, bispecific drugs, targeted therapies in the field of immune-oncology, unique cytokines that modify the immune system, and long-lasting peptides to treat metabolic and cardiovascular disorders. Ambrx is progressing with a broad range of clinical and preclinical programs to enhance effectiveness, safety, and convenience, in many medical fields, such as its principal candidate, ARX788.
How much funding has Ambrx raised?
Ambrx has raised $75.0M across 1 round on record. The most recent is an undisclosed round of $75.0M announced in May 2023.
When did Ambrx last raise funding?
Ambrx's most recent funding round on record is an undisclosed round of $75.0M, announced in May 2023.
Who is the CEO of Ambrx?
Lawson Macartney is listed as CEO at Ambrx.
Where is Ambrx headquartered?
Ambrx is based in La Jolla, California, United States.
How many employees does Ambrx have?
Ambrx is in the 101-250 employee band.
How does Ambrx's funding compare to other Biotechnology startups?
Ambrx's latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ambrx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ambrx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.